UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2021

ITEOS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-39401 (Commission File Number) 84-3365066 (I.R.S. Employer Identification No.)

iTeos Therapeutics, Inc. 139 Main Street Cambridge, Massachusetts 02142 (Address of principal executive offices, including zip code)

(339) 217-0161 (Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trade	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, \$0.001 par value per share	ITOS	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On January 11, 2021, the Company posted to the "Investors" section of the Company's website at <u>www.iteostherapeutics.com</u> an updated corporate presentation providing an updated corporate overview (the "Company Presentation"). A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 5.02 shall be deemed furnished, and not filed:

99.1 <u>iTeos Therapeutics, Inc. Corporate Presentation dated January 11, 2021.</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ITEOS THERAPEUTICS, INC.

Date: January 11, 2021

By: /s/ Michel Detheux Michel Detheux President and Chief Executive Officer



Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021 This Presentation has been prepared by iTeos Therapeutics, Inc. ("we," "us," our "our") and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assurptions regarding the future of our business, future plans and strategies, our development plans, our clinical results and future conditions. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," should," "arget," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include statements about the initiation, timing, progress and results of our current and future trends, includies of our product candidates; including our clinical flials of long-448 and of our research and development programs; our ability to successfully establish or maintain collaborations or strategic relationships for our product candidate; our apulate to and scale up manufacturing of our product candidates, including hur othis limited to our precise; the effect of the COVID-19 pandemic, leading miligation effects, and any of the foregoing or other aspects of our business operations, including mut limited to our place undue relinical triads; and our place candidates which involver riss and statements, and purposed and future

Such risks and uncertainties include, among others: uncertainties inherent in clinical studies and the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of a trial; that the results from our clinical trials for Inupadenant and EQS-448 may not support further development and marketing approval; the risk that we may be unable to gain approval for our product candidates on a timely basis, if at all; the risk that the current COVID-19 pandemic will impact our clinical trials and operations; and other risks set forth under the caption 'Risk Factors' in our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as filed with the SEC on November 12, 2020, and in our future filings with the SEC available at the SEC's website at www.sec.gov. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Certain information contained in this Presentation and statements made orally during this Presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party studies, publications, surveys and other data to be reliable as of the date of the Presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent sources has evaluated the reasonableness or accuracy of the Company's internal estimates or research and no reliance should be made on any information or statements made in this Presentation relating to or based on such internal estimates and research.

While we may elect to update these forward-looking statements at some point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

iTeos Made Progress in 2020 Building the Foundation to Support the Evolution of our Pipeline



 Growing track record in immuno-oncology drug discovery and development relying on our deep expertise in the biology of the tumor microenvironment



- Inupadenant (EOS-850), an A_{2A} receptor antagonist, and EOS-448, an IgG1 antibody directed against TIGIT being developed in multiple indications and combinations.
- Both programs discovered internally with global rights retained by iTeos



Well capitalized with approximately \$340MM of cash on the balance sheet as of September 30, 2020



Have added key personnel to **accelerate development activities**. Significantly enhanced our research and drug development capabilities, particularly in clinical development, regulatory affairs and CMC in order to bring the next generation of immunotherapies to patients.

Pipeline of Promising Immuno-Oncology Product Candidates

Program	Trial Design	Indications	Preclinical	Phase 1	Phase 1b/2a	Phase 2/3	Initiation	Data
Adenosine A	A2A Receptor Anta	gonist						
	Monotherapy	Solid Tumors		-			Expansion initiated 2Q 2020	Updated results 2Q 2021
Inupadenant	+ pembrolizumab	Anti-PD-1-Resistant Melanoma					Initiated 3Q 2020	Safety 2Q 2021
	+ pembrolizumab	Castrate-Resistant Prostate Cancer					Initiated 3Q 2020	
	+ paclitaxel- carboplatin	Triple-Negative Breast Cancer			•		Initiated 4Q 2020	Safety 4Q 2021
Anti-TIGIT m	Ab FcγR-Engaging)						
	Dose Finding, PK/PD	Solid Tumors					Initiated 1Q 2020	Presentation of initia results 2Q 2021
EOS-448	+ IMID	Multiple Myeloma					Initiation mid-2021	Mid 2022
	+ pembrolizumab	Solid Tumors					Initiation mid-2021	Mid 2022
	+ Inupadenant	Solid Tumors					Initiation mid-2021	Mid 2022
Preclinical P	ipeline							
Adenosine pa	thway inhibitor	Oncology		•			Candidate selection 2021	

Inupadenant Potentially Best-in-Class Adenosine Receptor Antagonist

Phase 1/2 Program with Early Single Agent Activity




Inupadenant: Designed to Overcome Immunosuppression in the Tumor Microenvironment

iTeos scientists implemented rational drug design to overcome the shortcomings of other adenosine pathway drugs

iTeos A _{2A} Inupadenant Differentiation	Others
1 Maintains potency in high adenosine concentrations found in tumor micro- environment due to long residence time	Limited activity in the high adenosine concentrations found in tumor microenvironment
2 Continuous target coverage due to prolonged pharmacodynamics	Limited target coverage in tumor microenvironment
3 Higher selectivity for A _{2A}	Pan-adenosine receptor antagonists

Durable responses and target engagement observed in monotherapy dose escalation



Full pharmacodynamic effects were observed at 40mg BID and above

Notes: 1 Once daily doses 2 Twice daily doses. CRC: colorectal concer, NSCLC: non-small-cell lung carcinoma: TCC: transitional cell carcinoma: CRPC: castrate resistant prostate cancer; SCPC: small cell prostate cancer; TNBC: triple-negative breast cancer Bio: Twice daily dosing

Inupadenant Treatment Results: Confirmed PRs with Substantial Tumor Reduction

CHECKPOINT INHIBITOR-REFRACTORY METASTATIC MELANOMA:

- → 44% tumor reduction
- → Patient reported decreased pain & improved mobility
- ➔ Single-agent activity observed

Prior Treatments:	Inupadenant Treatment History:	
Heavily pre-treated with multiple CPIs	 Stable disease at 7 weeks 26% tumor reduction 	
 2 previous cycles of pembro 	PR at 16 weeks	
 1 previous cycle of ipi 	 44% tumor reduction 	
	Confirmed PR at 24 weeks	
Baseline	Week 16	
Posterior R c	Posterior R arm	
Anterior R a	rm Anterior R arm	

HEAVILY PRE-TREATED mCRPC:

- → 49% tumor reduction
- ➔ Patient reported decreased bone pain
- ➔ Single-agent activity observed

Prior Treatments:

Heavily pre-treated with 5


- previous rounds of therapy Prior treatments include antiandrogen therapy and 2 lines of
- chemotherapy

Target Lesions

TO1 Lymph node axillary right Lymph node axillary right

TO2 Lymph node para-aortic right Lymph node para-aortic right

TO3 Adrenal gland right Adrenal gland right



Inupadenant Treatment History:


Stable disease at 8 weeks

Confirmed PR at 30 weeks

40% tumor reduction

49% tumor reduction

PR at 16 weeks



Inupadenant Phase 1/2 Clinical Plan: Rapidly Expanding in Several Tumor Types in Multiple Combinations

Single Agent	Safety and PK/PD Expansion Cohorts	Signal-Seeking 2-Stage Expansions	
Dose Escalation (Completed)	Inupadenant Single-agent Melanoma, CRPC, Endometrial, NSCLC, (n=24) w/matched tumor biopsies	CRPC (n= up to 27)	Generation of additional data to analyze the MoA and the specific CRPC population for inupadenant
Advanced solid tumor patients	Inupadenant + Pembro	CRPC (n= up to 48)	Large market potential - Prostate tissue contains a non-canonical source of adenosine production
(n=21) Biomarker-rich study w/matched tumor biopsies	Solid Tumors (n=10)	Anti-PD-1-Resistant melanoma (n= up to 33)	Potential for Proof of Concept in PD-1 resistant patients
	Inupadenant + Chemo TNBC (n=6)	1L TNBC (n= up to 38)	Chemotherapy leads to immunogenic cell death and promotes necrosis and hypoxia that lead to adenosine production - CD73 expression is associated with a
Initial results reported at AACR 2020	Initial results of expansion cohorts in 2Q21		poor prognosis and reduced anti- tumor immunity
			TNBC: Triple Negative Breast Cancer CRPC: Castration Resistant Prostate Cancer NSCLC: Non-small Cell Lung Cancer 9


$\frac{\text{EOS-448}}{\text{Fc}\gamma\text{R-engaging Anti-TIGIT Antibody}}$

Currently in Dose Escalation Phase 1/2 Trial




EOS-448 is Designed to Enhance Anti-Tumor Immune Response Through T Cell Activation & FcγR Engagement

Multiple programs have demonstrated that IgG1 antibodies are well tolerated at effective doses




EOS-448's Ability to Block TIGIT is Associated with Superior Immune Activation




Aereo = 313M32 from US2016/0376365 A1; Genentech = 4, ID3 from WO2017/053748 A2; BMS = 22G2 from US2016/0176963 A1; Merck = Cione 31C6 from WO2016/028656vA1; Arcus = TiG1 from WO2017/152088 A1

FcγR Engagement Led to Preferential Depletion of Tregs, while Sparing Most Functional Effector T cells

EOS-448 selectively depletes Tregs, sparing most effector T cells



TIGIT^{HIGH} TILs have an exhausted phenotype compared to TIGIT^{LOW} TILs



EOS-448 Initial Clinical Plan: Biologically Driven with a Focus on Addressing Unmet Medical Needs

Single Agent	Combination POC Trials	Rationale
Dose Escalation (Ongoing)	EOS-448 + IMID Multiple Myeloma	 Strong biological rationale TIGIT upregulated on CD8+ T cells during progression In vivo model suggests that TIGIT expression in post-transplant setting is associated with exhausted T cells and shows benefit of IMID combination
Advanced solid tumor patients (n=30)	EOS-448 + pembrolizumab Solid Tumors	 High TIGIT expression observed in Tumor-infiltrating lymphocytes – frequently co-expressed with PD-1 Strong external validation by successful Ph II trials of aTIGIT/PD(L)-1 combo in NSCLC
Biomarker-rich study w/matched tumor biopsies	EOS-448 + Inupadenant Solid Tumors	 Complementary mechanisms of immunosuppression Targeting multiple immune cells in the tumor micro-environment Additive benefit observed in animal models
Anticipate reporting in 1H2021	Anticipate commencement in mid-2021	
TNBC: Triple Negative Breast Cancer CRPC: Castration Resistant Prostate Cancer NSCLC: Non-small Cell Lung Cancer		TNBC: Triple Negative Breast Cancer CRPC: Castration Resistant Prostate Cancer NSCLC: Non-small Cell Lung Cancer

iTeos has Built the Foundation to Support Transformative Acceleration in 2021



Company **well capitalized** to fund aggressive growth in preclinical and clinical operations

Significant data updates on both clinical programs in Q2 2021

Continue to progress **Inupadenant ongoing monotherapy and combination** studies in multiple solid tumor types. Advance **EOS-448 into combination studies** in both solid and liquid tumor types

Select lead for 3rd internally-discovered IO program to advance into clinical trials and continue to advance discovery engine



Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021